Filing summary
Entity and period: The supplied filing is StemCells, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, filed March 21, 2013. This does not match the request metadata naming Microbot Medical Inc. The filing reports annual results and includes unaudited fourth-quarter data.
Business context and reporting period
StemCells was a development-stage stem-cell therapeutics and research-tools company. Its lead candidate, HuCNS-SC human neural stem cells, was being studied for central nervous system conditions; it also sold research cell-culture products and reagents. No therapeutic product had received marketing approval.
Financial results and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Total revenue | $1.368 million | $1.221 million |
| Product sales | $856,000 | $663,000 |
| Licensing, grants and other revenue | $512,000 | $558,000 |
| Gross profit | $1.105 million | $1.006 million |
| Research and development expense | $15.847 million | $19.938 million |
| Operating expenses | $23.650 million | $29.082 million |
| Operating loss | $(22.546) million | $(28.076) million |
| Net loss | $(28.491) million | $(21.329) million |
| Net loss per share | $(0.99) | $(1.50) |
| Cash used in operating activities | $(19.869) million | $(22.058) million |
Annual gross margin was approximately 81% of total revenue. The larger 2012 net loss, despite lower operating expenses, reflected a $5.945 million loss from remeasuring warrant liabilities; 2011 included a $6.612 million warrant-liability gain. These noncash fair-value changes materially affected reported net income.
At year-end, cash and cash equivalents were $8.471 million and current marketable securities were $13.901 million, for $22.372 million in combined cash and highly liquid investments. Current assets were $24.041 million and current liabilities $5.097 million. Stockholders’ equity was $13.985 million. Bonds payable and capital-lease obligations totaled approximately $351,000; separately, contractual operating-lease payments totaled $17.177 million. Warrant liabilities were $9.265 million.
Fourth quarter 2012 (unaudited): Revenue was $211,000, operating expenses $6.949 million, other income (expense) a net gain of $4.034 million, and net loss $2.758 million, or $(0.07) per share. The quarterly results were volatile: the filing attributes other income or expense in 2012 to warrant fair-value changes.
Material changes versus the prior comparable period
- Revenue rose 12% year over year, mainly due to 29% growth in product sales from higher SC Proven product volumes. Licensing, grant and other revenue declined 8%.
- Operating expenses fell 19%; R&D expense fell 21%, reflecting lower personnel, facility and external-service costs, among other factors.
- Net loss increased by approximately $7.2 million, principally because the warrant valuation shifted from a gain in 2011 to a loss in 2012.
- Operating cash use improved by approximately $2.2 million, while combined cash and highly liquid investments rose $5.8 million. Financing included approximately $20.452 million of gross proceeds from common-stock sales and $6.453 million from warrant exercises.
- Common shares outstanding increased from 22.428 million at year-end 2011 to 37.506 million at year-end 2012. The company reported 38,877,586 shares outstanding on March 4, 2013.
Outlook, developments and risks
- Management expected continued operating losses and did not expect profitability for several years. It said additional capital was necessary and warned existing resources might not fund operations beyond the next 12 months; financing might not be available on acceptable terms or at all.
- HuCNS-SC development remained early-stage. The PMD Phase I trial showed preliminary evidence of new myelination in four patients; three had modest functional gains and one remained stable. In the spinal-cord-injury trial, two of three patients in the first cohort had sensory-function gains at 12 months and one remained stable. A dry AMD Phase I/II trial had begun, with its first patient dosed in October 2012. These preliminary findings do not establish efficacy.
- CIRM approved a potential Alzheimer’s disease award of up to $20 million as a forgivable loan; terms were still under negotiation. The company elected in March 2013 not to borrow a separate potential $20 million CIRM award for cervical spinal cord injury.
- Key risks include dependence on HuCNS-SC and clinical outcomes, lengthy and uncertain regulatory review, manufacturing and patient-enrollment challenges, competition, patent and licensing exposure, and the need for further financing. Management also cited possible dilution from future equity issuance and outstanding warrants.
- Rhode Island facilities continued to impose costs. The company recorded $356,000 of 2012 wind-down expense and reported a $1.103 million year-end wind-down reserve. Its Neuralstem patent litigation remained ongoing, with discovery underway and a trial anticipated in 2013.
- The company signed a 10-year Sunnyvale lease in March 2013, with stated aggregate rent of approximately $3.5 million. It also reported subsequent equity and warrant exercises in February 2013.
Most important facts for investors to verify
- Confirm the issuer identity: the filing is for StemCells, Inc., not Microbot Medical Inc.
- Review the latest cash, investment balances, operating cash burn, financing capacity and management’s liquidity warnings.
- Track share-count changes, remaining warrant terms and potential dilution from future financings.
- Assess clinical-trial updates against the preliminary, small-cohort results described here, and confirm the status and terms of the proposed CIRM Alzheimer’s loan.
- Check subsequent developments in the Neuralstem litigation, patent portfolio, Rhode Island exit obligations and long-term lease commitments.